• Skip to main content
BC

biochimica clinica

en_US English
en_US English it_IT Italian
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

CONTRIBUTI SCIENTIFICI – Scientific Papers

Volume:

Biochimica Clinica 2013; 37(3) 190-194

Pubblicato on-line:

DOI:

Scarica in PDF:
Autenticazione richiesta

Antigene carboidratico 125 (CA-125) vs. proteina 4 dell’epididimo umano (HE4) in una popolazione di donne con massa pelvica

AUTORI

Marina Brugia1, Gaia Goteri2, Stefania Suppressa1, Vitangelo Scocco1, Massimo Tocchini1
1Laboratorio Analisi e 2Anatomia Patologica, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona

ABSTRACT

Carbohydrate antigen 125 (CA-125) vs. human epididymis protein 4 (HE4) in a population of women with pelvic mass

Aim of this study was to compare the diagnostic performance of CA-125 and HE4 for epithelial ovarian carcinoma (OC) in 505 consecutive women referred to our hospital for an adnexal mass. The population consisted of 18 (3.6%) patients with OC (13 in post-menopausal status, 72.2%) and 487 patients with a benign mass (171 in postmenopausal status, 35.1%). Employed diagnostic thresholds were 35 kU/L for CA-125 and 70 or 140 pmol/L for HE4 in pre-menopause and post-menopause, respectively. CA-125 and HE4 concentrations were significantly lower in patients with benign mass in comparison to women with OC. Overall sensitivity and specificity were higher for HE4 than for CA-125: 94.4% vs. 61.1% (P=0.04) and 91.0% vs. 82.8% (P=0.0002). False positive results for CA-125 and HE4 were found in 16.8% and 6.6% of women in pre-menopause and in 18.1% and 13.5% of women in postmenopause, respectively. Our results confirmed a higher specificity for HE4 vs. CA-125. Thus, the additional evaluation of HE4 would enable a more accurate referral of patients at risk for OC to the gynecological oncology services.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967